PlumX Metrics
Embed PlumX Metrics

Murine Hearing ABR/DPOAE Assessments in CMV-Infected Mouse Pups Receiving Peritoneal Antivirals of GCV, Quercetin+P188, or a Combination. Controls Include Infected and Untreated and Non-Infected and Treated. Second Dataset of Antiviral Assay in a Murine Stria Vascularis (SV) Monolayer Cell Culture

2023
  • 0
    Citations
  • 53
    Usage
  • 0
    Captures
  • 0
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

Dataset Description

Ganciclovir (GCV) has been shown to be an effective antiviral for the treatment of congenital cytomegalovirus (cCMV) induced sensorineural hearing loss. However, dose-dependent adverse effects (e.g. neutropenia) require strict, burdensome monitoring, limiting GCV use in some patients. Quercetin is a flavonoid with antioxidant properties that has demonstrated antiviral therapy against CMV. Although more benign than GCV, quercetin has limited therapeutic value due to its poor solubility. We previously reported that GCV improves hearing thresholds in a murine model of cCMV. We also noted that solubilizing quercetin with poloxamer 188 (P188) and combining with GCV therapy amplified CMV inhibition in murine stria vascularis (SV) endothelial cell cultures. We hypothesized that combination therapy with a lower dose of GCV and a soluble Quercetin-P188 solution (GCV+QP188) would improve hearing outcomes in a murine CMV model. BALB/c mice were infected with 200 plaque-forming units of murine CMV via intracerebral injection on postnatal day 3 (p3). Quercetin was solubilized in saline using P188 (QP188). Treatment groups received either 1 mg/kg GCV, 220 mg/kg of QP188, a combination therapy of GCV+QP188, or 220 mg/kg of P188 delivery vehicle BID at 12-hour intervals via intraperitoneal injection. All treatment groups were treated for 14 days starting at p3. Uninfected controls were treated with the combined regimen and P188 delivery vehicle. Auditory thresholds were assessed using distortion product otoacoustic emission (DPOAE) and auditory brainstem response (ABR) testing at 4, 6, and 8 weeks of age. Temporal bones from separate CMV-infected were harvested at p10, and viral load was determined by quantitative polymerase chain reaction. CMV-infected mice receiving combination therapy GCV+QP188 demonstrated significantly lower ABR (P

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know